Precision Medicine

Deploy disruptive innovation to develop precision-targeted therapies. We help you identify predictive biomarkers, develop and deploy diagnostic tests, and engage the most appropriate patient populations to demonstrate the safety and efficacy of your therapeutic products.

Accelerate the path to precision medicine

Experience and insights to help you to avoid obstacles and optimize your path to developing new personalized medicines and companion diagnostics. 

  • Through Q2 Solutions' Oncology Center of Excellence, our experts in biomarker discovery are providing a better understanding of therapeutic targets, molecular signaling, drug biology and patient response
  • Q2 Solutions' bioinformatics experts and scientists have published over 150 peer-reviewed articles in leading scientific journals since 2001 and have taken major roles in the FDA-led MAQC and SEQC projects
  • Adopt innovative new strategies for patient selection. We've developed dramatically more efficient means of enrolling rare, biomarker-defined patients - leveraging next-generation sequencing and our established site relationships
  • Q2 Solutions helped develop diagnostics for many of the biomarkers used today, including CTLA4, PD-1/PD-L1, BCR-Abl, ALK, BRAF, C-KIT, EGFR, KRAS and HER2

Extensive laboratory services across the development lifecycle

Our precision medicine laboratory services span the development lifecycle. We can begin with biomarker identification programs in early development and then progressively develop candidate biomarkers into research-appropriate tests and market-ready companion diagnostics. 

Early clinical development Recruitment and enrollment Post-approval
Genomics can help to identify patients who may respond most appropriately to a particular therapeutic. These results can help stratify populations in later phase trials. Enriching study populations using predictive biomarkers may improve efficacy signals while reducing drug development costs and timelines. Genomic insight can be used to optimize treatment decisions and ensure that the right drug is used to treat the right patient at the right time.

End-to-end integration

  • Biomarker identification 
  • Biomarker implementation
  • Companion diagnostics